Poly (ADP-ribose) polymerase (PARP) inhibitors as anticancer agents: An outlook on clinical progress, synthetic strategies, biological activity, and structure-activity relationship
-
Published:2024-08
Issue:
Volume:274
Page:116535
-
ISSN:0223-5234
-
Container-title:European Journal of Medicinal Chemistry
-
language:en
-
Short-container-title:European Journal of Medicinal Chemistry
Author:
Das Pronoy Kanti,
Matada Gurubasavaraja Swamy PurawargaORCID,
Pal RohitORCID,
Maji Lalmohan,
Dhiwar Prasad Sanjay,
Manjushree B.V.,
Viji M.P.
Reference166 articles.
1. An overview of targeted cancer therapy;Padma;Biomedicine,2015
2. An assessment of EGFR and HER2 inhibitors with structure activity relationship of fused pyrimidine derivatives for breast cancer: a brief review;Dhiwar;J. Biomol. Struct. Dyn.,2024
3. An outlook of docking analysis and structure-activity relationship of pyrimidine-based analogues as EGFR inhibitors against non-small cell lung cancer (NSCLC);Pal;J. Biomol. Struct. Dyn.,2023
4. Cancer statistics for the year 2020: an overview;Ferlay;Int. J. Cancer,2021
5. Hallmarks of cancer: the next generation;Hanahan;Cell,2011